Class / Patent application number | Description | Number of patent applications / Date published |
514261100 | Exactly five ring nitrogens in the bicyclo ring system (e.g., triazolo[4,5-d]pyrimidine, etc.) | 35 |
20080234296 | Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists - The use of a compound of formula (I): | 09-25-2008 |
20080312257 | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists - The present invention is directed to novel bicyclic triazolopyrimidine compounds of Formula (I) or a form thereof: | 12-18-2008 |
20090012103 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): | 01-08-2009 |
20090036471 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors - This invention concerns compounds of formula | 02-05-2009 |
20090247556 | Azolopyrimidines as Inhibitors of Cannabinoid 1 Activity - The invention provides compounds of formula (Ia), (Ic), (Ig) and (Ik), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1). | 10-01-2009 |
20100069408 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition - The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. | 03-18-2010 |
20100130515 | Polymorphs and solvates of a pharmaceutical and method of making - Polymorphic and solvated forms of solid 3-(4-amino-3-methylbenzyl)-7-(furan-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine, and methods of making them, are described. | 05-27-2010 |
20100137340 | FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS - The invention relates to compounds of Formula (I) wherein the substituents are as defined in claim | 06-03-2010 |
20100160349 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS - This invention concerns a compound of formula | 06-24-2010 |
20100173914 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Compounds that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning. | 07-08-2010 |
20100298350 | Triazolo[4,5-D]Pyrimidine Compounds For Treatment Of Abdominal Aortic Aneurysms - The invention provides triazolo [4,5-d]pyrimidine compounds, acting as P | 11-25-2010 |
20100324074 | Protein Kinase Inhibitors - The present invention is directed to low molecular weight and orally bioavailable 3H-[1,2,3]triazolo[4,5-d]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the tyrosine kinase MET. The invention is also directed to compositions which comprise these compounds, and methods of using them to treat cancer in mammals. | 12-23-2010 |
20110118285 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS - Selected fused imidazole or triazole derivatives are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 05-19-2011 |
20110118286 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS - The present invention relates to Bicyclic Heterocycle Derivatives of Formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR) in a patient. | 05-19-2011 |
20110172252 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS - Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning. | 07-14-2011 |
20110269778 | NOVEL DIPHENYL PURINE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - This invention relates to novel (6-phenyl-5-amino/nitro-pyrimidin-4-yl)-phenyl-amines, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 11-03-2011 |
20120077826 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: | 03-29-2012 |
20120122892 | CHEMICAL COMPOUNDS - This invention relates to novel compounds having the formula (I): | 05-17-2012 |
20120165348 | Novel compounds - The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. | 06-28-2012 |
20120190697 | HIV INHIBITING BICYCLIC PYRIMIDINE DERIVATIVES - HIV replication inhibitors of formula | 07-26-2012 |
20130040970 | Co-Crystals Of A Triazolo [4,5-D] Pyrimide Platelet Aggregation Inhibitor - The present invention relates to novel co-crystal forms of the compound of formula (I); wherein the co-former molecule is selected from glycolic acid, salicylic acid, decanoic (capric) acid, gentisic acid (2,5-dihydroxybenzoic acid), glutaric acid, vanillic acid (4-hydroxy-3-methoxybenzoic acid), succinic acid, malonic acid or maltol (3-hydroxy-2-methyl-4-pyrone); and to processes for their preparation, to pharmaceutical compositions containing such co-crystals, to the use of such co-crystals in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of a co-crystal of the compound of formula (I). | 02-14-2013 |
20130072503 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION - The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. | 03-21-2013 |
20130109702 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | 05-02-2013 |
20130131087 | Pharmaceutical Compositions - The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1α, 2α, 3β(1S*,2R*),5β]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol. | 05-23-2013 |
20130184295 | METHOD OF IDENTIFYING THERAPIES FOR PULMONARY HYPERTENSION - The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound. | 07-18-2013 |
20130245044 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS - Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning. | 09-19-2013 |
20130310401 | METHOD AND KITS FOR DETERMINING PLATELET SUSCEPTIBILITY TO ACTIVATION IN A PATIENT - The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient. | 11-21-2013 |
20140148472 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF - Disclosed are compounds able to modulate the activity of the GPR17 receptor in a highly specific way, which are useful in the treatment and diagnosis of diseases or dysfunctions involving the activation of said receptor. In particular, the compounds according to the invention can be used for neuroprotective and/or reparatory purposes, in cerebral, cardiac and renal ischaemia, in cerebral trauma, in chronic neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), and in demyelinating diseases such as multiple sclerosis. | 05-29-2014 |
20140256747 | Synthesis of Triazolopyrimidine Compounds - The present invention relates to the field of organic synthesis and describes the synthesis of specific triazolopyrimidine compounds and intermediates thereof as well as related derivatives. | 09-11-2014 |
20140296258 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITON - The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. | 10-02-2014 |
20150291602 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS - Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning. | 10-15-2015 |
20150329546 | NOVEL CRYSTALLINE FORM OF TICAGRELOR AND PROCESS FOR THE PREPARATION THEREOF - The present invention refers to a new crystalline form of ticagrelor, a process for the preparation thereof, pharmaceutical compositions comprising said new crystalline form of ticagrelor, and the use of the new crystalline form of ticagrelor as medicament | 11-19-2015 |
20150353545 | QUORUM SENSING INHIBITORS - The invention relates to compounds for use as quorum sensing inhibitors, and in particular, to quorum sensing inhibitors of | 12-10-2015 |
20150371007 | PHARMACEUTICAL PRODUCT AND COMMUNICATION TOOL - The present invention relates to a substance with pharmaceutical activity against a medical condition for use in a treatment of said medical condition in combination with a computer program product comprising instructions causing a computer to perform a method comprising the steps providing a patient with a set of questions according to a question schedule, wherein said set of questions is specific to the pharmaceutical product; collecting answers to said questions from said patient; subjecting said answers to a set of functions specific for the set of questions and the pharmaceutical product thereby generating patient specific feedback information; providing said feedback information to the patient; and optionally extracting clinically relevant information from said answers and providing said clinically relevant information to a database adapted for collecting clinically relevant information during clinical use of said substance. The invention further relates to a corresponding kit-of-parts comprising the substance and the computer program product, and the computer program product and its method as such. | 12-24-2015 |
20190142794 | PHARMACEUTICAL COMPOSITION CONTAINING GINKGOLIDE B AND ADP RECEPTOR ANTAGONIST, PREPARATION METHOD THEREOF AND USE THEREOF | 05-16-2019 |